A Phase 2 Prospective Interventional Open-Label Multi-Site Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 (OV935) as Adjunctive Therapy in Patients with Rare Epilepsy

Brief description of study

The purpose of this research study, is to obtain information about the safety of TAK-935 up to two years of treatment in patients with rare epilepsy who participated in a previous TAK-935 clinical study. This research study also aims to obtain information about long term effects of TAK-935 on seizure frequency. TAK-935 is a new investigational drug which is being studied for the treatment of epilepsy. TAK-935 reduces the activity of an enzyme called cholesterol 24-hydroxylase (C24H); product of this enzyme are thought to play an important role in disorders like epilepsy. An investigational or study drug means it has not been approved for us by the Federal Drug Agency (FDA).

Clinical Study Identifier: s19-01361
ClinicalTrials.gov Identifier: NCT03635073
Principal Investigator: Heather Ann Lau.
Other Investigator: Orrin Devinsky.

If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.